You must be a subscriber to see the full results of your search.
Please log in or subscribe below if you are not already a subscriber.
The Daily News subscribers get full access to more than
million names and addresses along with powerful search and download features.
Get the business leads you need with powerful searches of public records and notices.
Download listings into your spreadsheet or database.
Learn more about our services
| Search again
Editorial Results (free)
1. EpiPen Maker Finalizes Settlement for Government Overcharges
- Friday, August 18, 2017
EpiPen maker Mylan has finalized a $465 million federal agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade – charges brought after rival Sanofi filed a whistleblower lawsuit and tipped off the government.
2. Mylan, Like Other Generic Drugmakers, Feels the Pricing Pain
- Thursday, August 10, 2017
NEW YORK (AP) – Mylan's second-quarter profit and revenue surged, but not as much as Wall Street had expected and the company is taking a more conservative view going forward because of "ongoing challenges and the uncertain U.S. regulatory environment."
3. Drugmakers Pledge Restraint, But Prices Will Still Soar
- Tuesday, February 28, 2017
TRENTON, N.J. (AP) – Several big drugmakers are trying to quell the ongoing furor over high drug prices by revealing more information about their pricing and even pledging to keep a lid on increases.
4. Company Announces Pause for Drug After Price Criticism
- Wednesday, February 15, 2017
WASHINGTON (AP) – Marathon Pharmaceuticals announced Monday that it will temporarily halt the rollout of a drug to treat genetic muscle deterioration just hours after two members of Congress expressed outrage that the company planned to charge $89,000 a year for a drug that's widely available abroad for about $1,000 a year.
5. After Harsh Light, a Cheaper Version of EpiPen From Mylan
- Monday, December 19, 2016
Mylan is releasing a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew scorn from parents nationwide and spawned Congressional inquiries.
6. Pfizer Fined for Hiking Epilepsy Drug Price 2,600 Pct in UK
- Thursday, December 8, 2016
LONDON (AP) – British regulators fined U.S. drugmaker Pfizer and distributor Flynn Pharma a record 89.4 million pounds ($112.7 million) Wednesday for increasing the cost of an epilepsy drug by as much as 2,600 percent.
7. EpiPen Manufacturer Will Be a No-Show at Senate Hearing
- Tuesday, November 22, 2016
WASHINGTON (AP) – Pharmaceutical company Mylan is refusing to testify at a congressional hearing next week on a settlement between the company and the Justice Department over its life-saving EpiPen.
8. Mylan is Target of 2 Probes, Has 3Q Loss Due to EpiPen Fine
- Friday, November 11, 2016
TRENTON, N.J. (AP) – The maker of EpiPen emergency allergy injectors, under a microscope for repeatedly jacking up the price of the life-saving device, revealed Wednesday that it's a target of two price-related probes by federal agencies and has had its premises searched.
9. Mylan to Pay $465M Settlement Over Medicaid EpiPen Rebates
- Monday, October 10, 2016
Drugmaker Mylan will pay $465 million to settle allegations that it overbilled Medicaid for its life-saving EpiPen, ending one of the controversies over the soaring price of the emergency allergy injection.
10. The Pluses and Minuses of Drugmakers' Discount Cards
- Thursday, September 15, 2016
WASHINGTON (AP) – Facing public furor for the price of its emergency allergy shot EpiPen, Mylan Pharmaceuticals quickly pointed to a familiar industry solution: copay discount cards.
Copay coupons or cards have become a ubiquitous part of the pharmaceutical business, offered through websites, mobile apps and doctor's offices. Patient advocates say they can bring down out-of-pocket expenses for patients who face high copays and deductibles. Mylan last month boosted its discount cards to cover $300 of insured patients' copay costs, up from $100.
11. Pfizer, Allergan $160B Deal Forms World's Largest Drugmaker
- Tuesday, November 24, 2015
Pfizer and Allergan are joining in the biggest buyout of the year, a $160 billion stock deal that will create the world's largest drugmaker.
It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.
12. Supreme Court Weighs Generic Drug Dispute
- Thursday, October 16, 2014
WASHINGTON (AP) – The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.
13. Supreme Court Takes Up Drug Company Dispute
- Tuesday, April 1, 2014
WASHINGTON (AP) – The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.
14. FDA: New Suppliers to Ease 2 Cancer Drug Shortages
- Wednesday, February 22, 2012
TRENTON, N.J. (AP) – Federal regulators have approved new suppliers for two crucial cancer drugs, easing critical shortages that had been ratcheting up fears that patients, particularly children with leukemia, would miss lifesaving treatments.
15. Ranbaxy Gets Final FDA OK for Generic Glaxo Drug
- Wednesday, August 12, 2009
NEW YORK (AP) - Generic drugmaker Ranbaxy Laboratories Ltd. said Tuesday its U.S. subsidiary received final U.S. Food and Drug Administration approval on two generic doses of the migraine drug Imitrex.
16. Archived Article: Claritin P2
- Monday, August 12, 2002
Claritin copycats might hit market soon
Claritin copycats might hit market soon
A federal judge ruled patent claims on a derivative of allergy drug Claritin are invalid, a decision that could enable rival firms to sell copycat forms of Scher...
17. Archived Article: Benchmark
- Thursday, October 18, 2001
Court ruling might
Court ruling might
hurt consumer suits
A federal appellate court decision on a contested patent extension for Bristol-Myers Squibb Co.'s anti-anxiety drug BuSpar might aid the drug company's defense in upcoming lawsuits f...